Imipenem/cilastatin/relebactam efficacy, safety and probability of target attainment in adults with hospital-acquired or ventilator-associated bacterial pneumonia among patients with baseline renal impairment, normal renal function, and augmented renal clearance.

Roberts, Jason A; Nicolau, David P; Martin-Loeches, Ignacio; Deryke, C Andrew; Losada, Maria C; Du, Jiejun; Patel, Munjal; Rizk, Matthew L; Paschke, Amanda; Chen, Luke F

Roberts, Jason A; Nicolau, David P; Martin-Loeches, Ignacio; Deryke, C Andrew; Losada, Maria C; Du, Jiejun; Patel, Munjal; Rizk, Matthew L; Paschke, Amanda; Chen, Luke F.

Affiliation

Roberts JA; Faculty of Medicine, Centre for Clinical Research, The University of Queensland, Brisbane, Australia.
Nicolau DP; Herston Infectious Diseases Institute (HeIDI), Metro North Health, Brisbane, Australia.
Martin-Loeches I; Departments of Pharmacy and Intensive Care Medicine, Royal Brisbane and Women's Hospital, Brisbane, Australia.
Deryke CA; Division of Anesthesiology Critical Care Emergency and Pain Medicine, Nîmes University Hospital, University of Montpellier, Nîmes, France.
Losada MC; Center for Anti-Infective Research & Development, Hartford Hospital, Hartford, CT, USA.
Du J; Department of Intensive Care Medicine, St James's Hospital, Dublin, Ireland.
Patel M; Merck & Co., Inc., Rahway, NJ, USA.
Rizk ML; Merck & Co., Inc., Rahway, NJ, USA.
Paschke A; Merck & Co., Inc., Rahway, NJ, USA.
Chen LF; Merck & Co., Inc., Rahway, NJ, USA.

JAC Antimicrob Resist ; 5(2): dlad011, 2023 Apr.

Article in En | MEDLINE | ID: mdl-36880088

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Clinical_trials / Risk_factors_studies Language: En Journal: JAC Antimicrob Resist Year: 2023 Document type: Article Affiliation country: Australia Country of publication: Reino Unido

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google